
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Kim Noonan, MS, RN, ANP, AOCN, chief nurse practitioner, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the challenges of treating patients with multiple myeloma.
Kim Noonan, MS, RN, ANP, AOCN, chief nurse practitioner, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the challenges of treating patients with multiple myeloma.






